EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Sonic Hedgehog Pathway Modulation in Medulloblastoma: Focus on Vismodegib (GDC‐0449)

Amir Modarresi Chahardehi, Reza Arefnezhad, Laleh Firouzi, Reza Nasiri, Mohammad Saeed Soleimani Meigoli, Hossein Fatemian, Sina Rahimi, Ali Dastjerdi, Pegah Refahi, Fatemeh Ojaghlou, Mahya Banafshe, Fatemeh Rezaei-Tazangi und 1 weitere

Developmental Neurobiology · 2026

DOI: 10.1002/dneu.70009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Developmental Neurobiology, 2026. Verfasst von Amir Modarresi Chahardehi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran. Hauptthemen laut MEDLINE: Anilides, Pyridines, Medulloblastoma, Hedgehog Proteins. Die Arbeit nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medulloblastoma (MB) is the most common malignant brain tumor in children, classified into four molecular subgroups: WNT, sonic hedgehog (SHH), Group 3, and Group 4. The SHH pathway is crucial in the pathogenesis of SHH‐subgroup MB (SHH‐MB), influenced by mutations in patched homolog 1 (PTCH1), smoothened (SMO), and suppressor‐of‐fused (SUFU). Targeting this route has shown potential, with vismodegib, an SMO inhibitor, demonstrating effectiveness in both preclinical and clinical investigations. Notwithstanding its therapeutic promise, vismodegib's systemic toxicity, especially bone abnormalities in pediatric patients, constrains its application. Novel techniques, such as nanoparticle formulations and intraventricular administration, have optimized medication distribution, diminished toxicity, and augmented effectiveness. Research indicates vismodegib's efficacy in enhancing progression‐free survival (PFS) and addressing tumor‐specific genetic abnormalities. Nonetheless, obstacles, such as resistance stemming from SMO mutations and developmental toxicity, remain. Prospects encompass the enhancement of drug delivery methods, the integration of SHH inhibitors with alternative therapeutics, and the advancement of next‐generation inhibitors to surmount resistance. Hence, these developments offer potential for improving outcomes in SHH‐MB while reducing side effects, especially in pediatric populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesPyridinesMedulloblastomaHedgehog ProteinsSignal TransductionAntineoplastic AgentsCerebellar NeoplasmsHumansAnimals

Stichwörter der Autor:innen

brain tumormedulloblastomapediatric brain tumorsmoothened inhibitorsonic hedgehog (SHH) pathwaytargeted therapyvismodegib

Substanzen

AnilidesHhAntag691PyridinesHedgehog ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran.
  • Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Coenzyme R Research Institute, Tehran, Iran.
  • School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran.
  • Young Researchers and Elite Club, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

Zitieren

APA

Chahardehi, A. M., Arefnezhad, R., Firouzi, L., Nasiri, R., Meigoli, M. S. S., Fatemian, H., Rahimi, S., Dastjerdi, A., Refahi, P., Ojaghlou, F., Banafshe, M., Rezaei-Tazangi, F., & Tavakoli, M. R. (2026). Sonic Hedgehog Pathway Modulation in Medulloblastoma: Focus on Vismodegib (GDC‐0449). Developmental Neurobiology. https://doi.org/10.1002/dneu.70009

Vancouver

Chahardehi AM, Arefnezhad R, Firouzi L, Nasiri R, Meigoli MSS, Fatemian H, et al. Sonic Hedgehog Pathway Modulation in Medulloblastoma: Focus on Vismodegib (GDC‐0449). Developmental Neurobiology. 2026. doi:10.1002/dneu.70009

BibTeX
@article{Chahardehi2026,
  author = {Chahardehi, Amir Modarresi and Arefnezhad, Reza and Firouzi, Laleh and Nasiri, Reza and Meigoli, Mohammad Saeed Soleimani and Fatemian, Hossein and Rahimi, Sina and Dastjerdi, Ali and Refahi, Pegah and Ojaghlou, Fatemeh and Banafshe, Mahya and Rezaei-Tazangi, Fatemeh and Tavakoli, Marziye Ranjbar},
  title = {Sonic Hedgehog Pathway Modulation in Medulloblastoma: Focus on Vismodegib (GDC‐0449)},
  journal = {Developmental Neurobiology},
  year = {2026},
  doi = {10.1002/dneu.70009}
}
Kostenlos starten →